Tag: Bradykinesia


LEVODOPA

Introduction to Levodopa (L-dopa) Levodopa, chemically known as L-3,4-dihydroxyphenylalanine, or more commonly referred to as L-dopa, represents the most critical therapeutic agent in the management of Parkinson’s disease (PD) and related movement disorders characterized by dopamine depletion. PD is pathologically defined by the degeneration of dopaminergic neurons in the substantia nigra, leading to a profound […]

Read More

PSEUDOPARKINSONISM

Pseudoparkinsonism: A Review Abstract Pseudoparkinsonism is a neurological disorder characterized by the presence of parkinsonian-like symptoms, such as bradykinesia, rigidity, and tremor, without any evidence of degeneration of the dopaminergic pathways in the brain. This disorder occurs as a result of various medications and medical conditions that interfere with normal central nervous system functioning. In […]

Read More